Drug intelligence / Profile preview

ReCOV

Development stage: Phase 3
Lead developer: Recbio
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ReCOV is a recombinant protein subunit vaccine developed for the prevention of COVID-19. It is designed to induce an immune response against SARS-CoV-2, the virus responsible for COVID-19, by presenting a portion of the viral spike protein to stimulate protective immunity. The vaccine uses recombinant technology to produce the antigenic component and is administered as an injection. ReCOV has been evaluated in clinical trials for its safety and efficacy in preventing COVID-19.

Brand names: ReCOV
Other names: RBD-Fc/NTD-Fc vaccinetwo-component recombinant COVID-19 vaccinerecombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine

Targets

S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on ReCOV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReCOV.

Explore the full profile